CNBCNovo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, OzempicJan 31Elliot SmithBy Elliot Smithmore_vert
BloombergNovo Nordisk (NOVOB) Earnings Surge on Wegovy FrenzyJan 31Kit Rees & Naomi KresgeBy Kit Rees & Naomi Kresgemore_vert
The GuardianObesity drug boom pushes Novo Nordisk shares to record highJan 31Julia KolleweBy Julia Kollewemore_vert
CNBCNorway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar clubJan 31Sam MeredithBy Sam Meredithmore_vert
Yahoo FinanceNovo Nordisk earnings: 'I could smile a long time over results like this,' says CFO KnudsenJan 31Anjalee KhemlaniBy Anjalee Khemlanimore_vert
The Motley FoolWill Novo Nordisk Be a $1 Trillion Company by 2030?Jan 30Adam SpataccoBy Adam Spataccomore_vert
ReutersNovo Nordisk expects double-digit growth as it boosts Wegovy suppliesJan 31Maggie Fick & Jacob GronholtBy Maggie Fick & Jacob Gronholtmore_vert
FortuneWegovy, Ozempic drive Novo Nordisk to $500 billion valuationJan 31Ryan HoggBy Ryan Hoggmore_vert
The Washington PostNovo Nordisk profit surges as it boosts supplies of WegovyJan 31Daniel GilbertBy Daniel Gilbertmore_vert
ForbesOzempic Maker Novo Nordisk Beats Profit Forecasts As Weight-Loss Sales SoarJan 31Robert HartBy Robert Hartmore_vert
New York Post Ozempic and Wegovy maker Novo Nordisk now worth $500B amid soaring popularityJan 31Ariel ZilberBy Ariel Zilbermore_vert